Medication Adherence for Patients with Severe Mental Illness.

Petauri PACT Executive Briefings - 3-Minute Market Insights

Send us a text

Medication Adherence for Patients with Severe Mental Illness.

Adherence to prescribed medication regimens improves outcomes for patients with severe mental illness, such as schizophrenia, bipolar disorders, and major depressive disorder. Psychiatric disorders are a significant public health problem: schizophrenia affects about 23 million people worldwide, bipolar disorders affect about 60 million worldwide, and major depressive disorder affects another 350 million, people worldwide. Major depressive disorder is considered by many to be the most damaging psychiatric disorder and is associated with substantial disability, morbidity, mortality, and cost.

Medication therapy is essential for the successful management of patients with serious mental illness. Medication non-adherence is highly prevalent, ranging between 63–74% in patients with schizophrenia1, about 50% in patients with bipolar disorders1, and as high as 60% in patients with major depressive disorder. About 25% of patients discontinue their medication within the first week after discharge from inpatient treatment. Further, the World Health Organization has reported that for persons with mental health issues and other, comorbid chronic diseases, medication nonadherence is 50%. Nonadherence is defined as taking less than 80% of prescribed doses, which has been validated in predicting future hospitalization rates.
Need more information? As always, if you need a deeper dive into any of these topics, please don’t hesitate to reach out.

Check out @The Kinetix Group‘s growing library of TKG PACT Executive Briefings where you can listen and download the companion PDF infographics.

https://tkgpact.com/executive-briefings/